Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.2
(20.0%)
USD 1.2
(20.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 140.71 Million USD | 11.15% |
| 2021 | 126.59 Million USD | 15.74% |
| 2020 | 109.38 Million USD | -3.35% |
| 2019 | 113.18 Million USD | 7.86% |
| 2018 | 104.92 Million USD | 0.87% |
| 2017 | 104.02 Million USD | 25.97% |
| 2016 | 82.57 Million USD | 71.96% |
| 2015 | 48.02 Million USD | 83.69% |
| 2014 | 26.14 Million USD | 77.2% |
| 2013 | 14.75 Million USD | -23.18% |
| 2012 | 19.2 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 37.48 Million USD | 0.68% |
| 2023 Q1 | 37.23 Million USD | 18.7% |
| 2022 Q1 | 28.29 Million USD | 17.33% |
| 2022 FY | 140.71 Million USD | 11.15% |
| 2022 Q2 | 48.26 Million USD | 70.62% |
| 2022 Q3 | 32.78 Million USD | -32.07% |
| 2022 Q4 | 31.36 Million USD | -4.33% |
| 2021 FY | 126.59 Million USD | 15.74% |
| 2021 Q3 | 41.77 Million USD | 57.35% |
| 2021 Q4 | 24.11 Million USD | -42.28% |
| 2021 Q2 | 26.54 Million USD | -22.3% |
| 2021 Q1 | 34.16 Million USD | 23.87% |
| 2020 Q3 | 22.52 Million USD | -10.24% |
| 2020 Q1 | 34.18 Million USD | 1.22% |
| 2020 Q2 | 25.09 Million USD | -26.59% |
| 2020 Q4 | 27.58 Million USD | 22.45% |
| 2020 FY | 109.38 Million USD | -3.35% |
| 2019 Q2 | 26.18 Million USD | 6.81% |
| 2019 Q4 | 33.77 Million USD | 17.63% |
| 2019 Q3 | 28.7 Million USD | 9.64% |
| 2019 FY | 113.18 Million USD | 7.86% |
| 2019 Q1 | 24.51 Million USD | 14.91% |
| 2018 Q3 | 19.85 Million USD | -36.47% |
| 2018 Q2 | 31.25 Million USD | -3.88% |
| 2018 Q1 | 32.51 Million USD | 42.85% |
| 2018 FY | 104.92 Million USD | 0.87% |
| 2018 Q4 | 21.33 Million USD | 7.46% |
| 2017 Q4 | 22.76 Million USD | -11.17% |
| 2017 Q2 | 30.38 Million USD | 16.41% |
| 2017 Q1 | 26.1 Million USD | -23.31% |
| 2017 FY | 104.02 Million USD | 25.97% |
| 2017 Q3 | 25.62 Million USD | -15.67% |
| 2016 Q1 | 17.64 Million USD | 22.65% |
| 2016 Q4 | 34.03 Million USD | 125.4% |
| 2016 Q3 | 15.1 Million USD | -4.36% |
| 2016 Q2 | 15.78 Million USD | -10.54% |
| 2016 FY | 82.57 Million USD | 71.96% |
| 2015 Q4 | 14.39 Million USD | 16.32% |
| 2015 FY | 48.02 Million USD | 83.69% |
| 2015 Q3 | 12.37 Million USD | 12.58% |
| 2015 Q2 | 10.98 Million USD | 6.99% |
| 2015 Q1 | 10.27 Million USD | 33.81% |
| 2014 Q3 | 9.74 Million USD | 34.97% |
| 2014 FY | 26.14 Million USD | 77.2% |
| 2014 Q4 | 7.67 Million USD | -21.22% |
| 2014 Q2 | 7.21 Million USD | 37.54% |
| 2014 Q1 | 5.24 Million USD | 33.45% |
| 2013 Q2 | 890.23 Thousand USD | -83.74% |
| 2013 Q1 | 5.47 Million USD | 31.92% |
| 2013 Q3 | 4.23 Million USD | 376.25% |
| 2013 FY | 14.75 Million USD | -23.18% |
| 2013 Q4 | 3.93 Million USD | -7.24% |
| 2012 Q3 | 4.43 Million USD | 0.0% |
| 2012 Q4 | 4.14 Million USD | -6.43% |
| 2012 FY | 19.2 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -1605.031% |
| Alpha Teknova, Inc. | 45.85 Million USD | -206.841% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 28.201% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -213.716% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 11.616% |
| Cosmos Health Inc. | 26.18 Million USD | -437.47% |
| Journey Medical Corporation | 54.59 Million USD | -157.746% |
| Embecta Corp. | 528.4 Million USD | 73.37% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 48.247% |
| Dynavax Technologies Corporation | 219.14 Million USD | 35.79% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 76.15% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 56.886% |
| PainReform Ltd. | 9.58 Million USD | -1368.218% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -972.15% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -972.15% |
| SCYNEXIS, Inc. | 51.84 Million USD | -171.397% |
| Safety Shot Inc | 12.1 Million USD | -1061.995% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -4484.731% |
| Procaps Group, S.A. | 199.47 Million USD | 29.459% |
| Theratechnologies Inc. | 72.75 Million USD | -93.405% |
| Harrow Health, Inc. | 89.97 Million USD | -56.396% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1389.668% |
| Biofrontera Inc. | 39.95 Million USD | -252.146% |
| DURECT Corporation | 43.71 Million USD | -221.89% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 73.401% |
| Cronos Group Inc. | 96.7 Million USD | -45.502% |
| OptiNose, Inc. | 85.1 Million USD | -65.347% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 39.38% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -259.395% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 1571.75% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 55.206% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -1346.063% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -226.934% |
| Radius Health, Inc. | 265.92 Million USD | 47.086% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -916.58% |
| ProPhase Labs, Inc. | 37.85 Million USD | -271.748% |
| Phibro Animal Health Corporation | 260.29 Million USD | 45.941% |
| Procaps Group S.A. | 187.24 Million USD | 24.85% |
| Alvotech | 285.43 Million USD | 50.702% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -1332.204% |
| Viatris Inc. | 5.96 Billion USD | 97.641% |
| Rockwell Medical, Inc. | 15.37 Million USD | -815.273% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -135.15% |
| SIGA Technologies, Inc. | 22.04 Million USD | -538.361% |
| Tilray Brands, Inc. | 251.35 Million USD | 44.018% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -186.949% |
| Shineco, Inc. | 17.94 Million USD | -684.008% |
| PetIQ, Inc. | 192.72 Million USD | 26.987% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -3425.661% |
| Incannex Healthcare Limited | 30.05 Million USD | -368.219% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 91.186% |
| Alimera Sciences, Inc. | 62.64 Million USD | -124.636% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -18354.489% |
| Assertio Holdings, Inc. | 368.58 Million USD | 61.823% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -2290.83% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -690.149% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -564.717% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -568.726% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 14.701% |
| Hempacco Co., Inc. | 7.59 Million USD | -1752.365% |
| Talphera, Inc. | 11.99 Million USD | -1073.203% |
| Alvotech | 285.43 Million USD | 50.702% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 59.202% |
| Currenc Group, Inc. | 24 Million USD | -486.257% |
| Kamada Ltd. | 45.42 Million USD | -209.765% |
| Indivior PLC | 911 Million USD | 84.554% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1033.909% |
| Flora Growth Corp. | 10.57 Million USD | -1230.126% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -568.726% |
| Evolus, Inc. | 189.75 Million USD | 25.846% |
| HUTCHMED (China) Limited | 436.23 Million USD | 67.743% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 8.707% |
| Akanda Corp. | 3.48 Million USD | -3939.434% |